Our Recommendations
- Beschluss der STIKO zur 19. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung (2022)
- Recommandations provisoires concernant l’utilisation du vaccin ChAdOx1-S [recombinant] contre la COVID-19 (vaccin anti-COVID-19 AZD1222 Vaxzevria™ d’AstraZeneca, COVISHIELD™ de SII) (2021)
- Statement on the Efficacy of the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19) against the SARS-CoV-2 Variants (2021)
- Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) (2022)
- Déclaration sur l’efficacité du vaccin COVID-19 d’AstraZeneca (ChAdOx1 nCoV-19) contre les variants du SARS-CoV-2 (2021)
New Publications
- Recomendações provisórias para o uso da vacina ChAdOx1-S [recombinante] contra COVID-19 (vacina AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™) - Última atualização em 30 de julho de 2021 (2021)
- Предварительные рекомендации по применению вакцины ChAdOx1-S [рекомбинантной] против COVID-19 (вакцина AstraZeneca COVID-19 AZD1222, Vaxzevria™, SII COVISHIELD™) (2021)
- Recommandations provisoires concernant l’utilisation du vaccin ChAdOx1-S [recombinant] contre la COVID-19 (vaccin anti-COVID-19 AZD1222 Vaxzevria™ d’AstraZeneca, COVISHIELD™ de SII) (2021)
- Documento de referência sobre a vacina AZD1222 contra COVID-19 desenvolvida pela Universidade de Oxford e pela AstraZeneca, 1 de março de 2021 (2021)
- Beschluss der STIKO zur 19. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung (2022)
Filter
26
Featured
Recommendations
6
Language
Document type
Fact sheets
14
Guidelines
6
Studies & Reports
4
Manuals
1
Situation Updates
1
Countries / Regions
West and Central Africa
3
East and Southern Africa
3
India
3
Germany
2
Brazil
2
South Sudan
2
Western and Central Europe
1
South Korea
1
Authors & Publishers
Publication Years
Category
Countries
12
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...
Comment The Lancet Volume 397, ISSUE 10269, P72-74, January 09, 2021
Published:December 08, 2020DOI:https://doi.org/10.1016/S0140-6736(20)32623-4
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...
Este documento de referência foi preparado pelo Grupo de Trabalho sobre Vacinas contra COVID-19 do Grupo Consultivo Estratégico de Especialistas em Imunização (SAGE) para orientar as discussões do SAGE em sua reunião extraordinária de 8 de fevereiro de 2021, que resultou na publicação do do...
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...
REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS
An overview of COVID-19 Vaccine AstraZeneca and why it is authorised in the EU. Available in 22 languages
18 Febr. 2021
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.
Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021
AstraZeneca-SKBio in South Korea and Serum Institute of India
